The market size for AChE inhibitors in 2024 is estimated to be US$21B and
is driven by the rising prevalence of Alzheimer's disease.
“These preliminary in vitro results are very promising, showing a clear pattern of neuronal cell protection and synergistic method of action.
AI-116 is Algorae’s combination drug candidate comprising Donepezil Hydrochloride (Donepezil), an acetylcholinesterase inhibitor (AChE inhibitor), and cannabidiol (CBD). AChE inhibitors are FDA registered first line treatments for Alzheimer’s Disease, which are also prescribed off-label for other neurodegenerative disorders, including Parkinson’s Disease and vascular dementia.
